- XPOVIO^® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).

- The approval of XPOVIO^® by the NHIS in South Korea is the fourth national reimbursement in the Antengene markets after mainland of China, Australia and Singapore.

- Additional reimbursements of XPOVIO^® in APAC markets are expected.

- Antengene has also submitted the new drug applications (NDAs) in additional ASEAN markets, including Thailand, Malaysia and Indonesia, where approvals are expected in the H2 of 2024.

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer,  announced that South Korea's National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO^® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM). The drug is expected to be officially included into the national reimbursed drugs list on July 1, 2024.

MM, the second most common hematologic malignancy, is caused by the dysregulated proliferation of plasma cells. Patients with MM face a range of challenges including a high relapse rate, short survival, and limited treatment options. According to market data, the global MM market has exceeded US$17 billion in 2023 and is expected to reach US$ 26 billion by 2028, with a compound annual growth rate (CAGR) of 8.7%^[1].

With a novel mechanism of action, XPOVIO^® is the world's first approved orally-available, selective XPO1 inhibitor. XPOVIO^® has a global commercial presence with approvals in over 40 countries and regions.

To date, XPOVIO^® has already been included for health insurance coverage in mainland of China, Australia and Singapore in the APAC markets. With the latest approval from the NHIS in South Korea, XPOVIO^® is poised to be a novel treatment option and will bring clinically meaningful survival benefits to more patients in need.

Antengene has already submitted NDAs for XPOVIO^® in Thailand, Malaysia and Indonesia for the treatment of patients with R/R MM and R/R diffuse large B-cell lymphoma (R/R DLBCL).